

1 **SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and**  
2 **clinics in Japan**

3

4 **Running title:** Seroprevalence of SARS-CoV-2 antibodies

5

6 Tatsuya Yoshihara, MD, PhD<sup>1</sup>; Kazuya Ito, PhD<sup>2,3</sup>; Masayoshi Zaitso, MD, PhD<sup>4</sup>;

7 Eunhee Chung, PhD<sup>5</sup>; Izumi Aoyagi, MD<sup>6</sup>; Yoshikazu Kaji, MD<sup>7</sup>; Tomomi Tsuru, MD<sup>8</sup>;

8 Takuma Yonemura, MD<sup>9</sup>; Koji Yamaguchi, MD<sup>10</sup>; Shinichi Nakayama, MD, PhD<sup>11</sup>;

9 Yosuke Tanaka, MD, PhD<sup>12</sup>; Nobuo Yurino, MD, PhD<sup>13</sup>; Hideki Koyanagi, MD, PhD<sup>14</sup>;

10 Shunji Matsuki, MD, PhD<sup>1</sup>; Ryuji Urae, MD<sup>15</sup>; and Shin Irie, MD<sup>15</sup>

11

12 <sup>1</sup>SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, 3-5-1 Kashiiteriha,

13 Higashi-ku, Fukuoka 813-0017, Japan

14 <sup>2</sup>SOUSEIKAI Clinical Epidemiological Research Center, 3-5-1 Kashiiteriha, Higashi-

15 ku, Fukuoka 813-0017, Japan

16 <sup>3</sup>College of Healthcare Management, Takayanagi 960-4, Setaka-machi, Miyama 835-

17 0018, Japan

18 <sup>4</sup>Department of Public Health, Dokkyo Medical University School of Medicine, 880

19 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan

20 <sup>5</sup>SOUSEIKAI Global Clinical Research Center, Kashiiteriha 3-5-1, Higashi-ku,

21 Fukuoka 813-0017, Japan

22 <sup>6</sup>SOUSEIKAI Fukuoka Mirai Hospital, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-

23 0017, Japan

24 <sup>7</sup>SOUSEIKAI Hakata Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

- 25 <sup>8</sup>SOUSEIKAI PS Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan
- 26 <sup>9</sup>SOUSEIKAI Sumida Hospital, 1-29-1, Honjo, Sumida-ku, Tokyo 130-0004, Japan
- 27 <sup>10</sup>SOUSEIKAI Nishikumamoto Hospital, 1012 Koga, Tomiainmachi, Minami-ku,  
28 Kumamoto 861-4157, Japan
- 29 <sup>11</sup>SOUSEIKAI Miyata Hospital, 1636 Honjo, Miyawaka, Fukuoka 823-0003, Japan
- 30 <sup>12</sup>SOUSEIKAI Kanenokuma Hospital, 3-24-16 Kanenokuma, Hakata-ku, Fukuoka 812-  
31 0863, Japan
- 32 <sup>13</sup>SOUSEIKAI Shinyoshizuka Hospital, 7-6-29, Yoshizuka, Hakata-ku, Fukuoka 812-  
33 0041, Japan
- 34 <sup>14</sup>SOUSEIKAI DoDo Clinic, 1-31-13, Nakaikegami, Ota-ku, Tokyo 146-0081, Japan
- 35 <sup>15</sup>SOUSEIKAI, 3-5-1 Kashiiteriha, Higashi-ku, Fukuoka 813-0017, Japan

36

37 **Corresponding author:**

38 Tatsuya Yoshihara, MD, PhD

39 Fukuoka Mirai Hospital, Clinical Research Center, Kashiiteriha 3-5-1, Higashi-ku,

40 Fukuoka, Japan 813-0017

41 Tel: +81-92-662-3608

42 Fax: +81-92-662-3612

43 E-mail: tatsuya-yoshihara@lta-med.com

44

45 **Keywords**

46 COVID-19, SARS-CoV-2, seroprevalence, antibody, healthcare workers

47

48 **Summary**

49 Coronavirus disease 2019 (COVID-19) has become a serious public health problem  
50 worldwide. However, little is known about the prevalence of COVID-19 among  
51 healthcare workers in Japan. We aimed to examine the seroprevalence of severe acute  
52 respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2,160 healthcare  
53 workers in general hospitals and clinics in Japan. The prevalence of SARS-CoV-2  
54 immunoglobulin G was 1.2% in August and October 2020, which is relatively higher than  
55 that in the general population in Japan. Because of the higher risk of COVID-19 infection,  
56 healthcare workers should be the top priority for further social support and vaccination  
57 against SARS-CoV-2.

58

## 59 **Introduction**

60 Coronavirus disease 2019 (COVID-19) has become a serious public health problem  
61 worldwide. In Japan, the confirmed cases of COVID-19 remained low as of December  
62 2020 compared with those in Europe or northern America. The low seroprevalence  
63 (0.03%–0.40%) of COVID-19 in the general population of Japan was reported in  
64 several studies conducted from June to September 2020 (1). However, the prevalence of  
65 COVID-19 among healthcare workers in Japan, who are at higher risk for COVID-19  
66 infection (2), is not well characterized. Here, we aimed to determine the seroprevalence  
67 of immunoglobulin (Ig)M and IgG antibodies against severe acute respiratory syndrome  
68 coronavirus-2 (SARS-CoV-2) among workers in general hospitals and clinics in Japan.

69

## 70 **Methods**

71 A multicenter prospective study was conducted in nine general hospitals and clinics of  
72 the SOUSEIKAI Medical Group: Fukuoka Mirai Hospital (FMH), Hakata Clinic (HC),  
73 PS Clinic (PC), Sumida Hospital (SH), Miyata Hospital (MH), Kanenokuma Hospital  
74 (KH), Shinyoshizuka Hospital (SYH), Nishikumamoto Hospital (NH), and DouDou  
75 Clinic (DC). These hospitals/clinics are not designated to treat COVID-19 patients.  
76 FMH Clinical Research Center, HC, NH Clinical Pharmacology Center, and SH are

77 specialized facilities for clinical trials (mainly Phase 1 clinical trials). FMH, PC, MH,  
78 KH, and SYH are located in Fukuoka prefecture; NH is located in Kumamoto  
79 prefecture; and DC and SH are located in Tokyo.

80 This study was approved by the SOUSEIKAI Hakata Clinic Institutional Review  
81 Board (approval number: N-105) and registered in the UMIN Clinical Trial Registry  
82 (registration number: UMIN000041262). The people working in the hospitals/clinics of  
83 the SOUSEIKAI Medical Group were invited to participate in the study. All participants  
84 provided a written informed consent. In each survey, a questionnaire was used to obtain  
85 the following data: job title, presence of suspected COVID-19 symptoms since February  
86 2020, and history of COVID-19 diagnosis. The participants' occupations were divided  
87 into eight categories: nurses (including nurse assistants), physicians, technicians  
88 (laboratory technicians, radiology technicians, pharmacists, clinical engineers, dental  
89 hygienists, physical therapists, occupational therapists, speech therapists, and  
90 acupuncturists), nursing care staff, office workers, receptionists, employees in clinical  
91 research units, and others (drivers, security personnel, nursery school teachers, shop  
92 workers, sanitary workers, nutritionists, and food service staff).

93 SARS-CoV-2-specific IgM and IgG antibodies in the venous blood were  
94 assessed using an immunochromatographic assay kit (2019-nCoV Ab Test [Colloidal

95 Gold], INNOVITA Biological Technology Co., Ltd., Tangshan, China) following the  
96 manufacturer's instructions. Blood samples were collected in August and/or October  
97 2020. Using descriptive statistics, the difference in seropositive rates across background  
98 characteristics was assessed using a chi-square test. Two-tailed P values of <0.05 were  
99 considered significant. Statistical analyses were performed using JMP Pro 15 (SAS  
100 Institute Inc. Japan, Tokyo, Japan).

101

## 102 **Results**

103 A total of 2,160 SOUSEIKAI workers, aged 20–83 years (mean = 41.9, standard  
104 deviation =12.7; women: 1,547 [71.6%]), underwent at least one antibody test in August  
105 and/or October. IgM and/or IgG SARS-CoV-2 antibodies were detected in 33 (1.5%)  
106 and 27 (1.3%) participants in August and October, respectively (Table 1). IgG  
107 antibodies against SARS-CoV-2 were detected in 25 (1.2%) and 24 (1.2%) participants  
108 in August and October, respectively. After excluding one facility, where nosocomial  
109 infections occurred in April 2020, 13 participants (0.8%) demonstrated IgG positivity in  
110 August and October (Table 1). Of the eight participants who showed IgM positivity in  
111 August, none reported IgG positivity in October. Among the participants who showed  
112 IgG positivity in August, 95.5% (21/22) demonstrated IgG positivity in October.

113           The prevalence of IgG antibodies was higher among the 20–29-year and 60–  
114 69-year age groups compared with other age groups, whereas no significant difference  
115 was observed between women and men (Table 2). The prevalence of IgG antibodies was  
116 relatively, but not significantly, higher among nurses, nursing care staff, and  
117 receptionists (Table 2). Among the 28 participants who had at least one IgG-positive test  
118 result, 17 (60.7%) had suspected symptoms of COVID-19 since February 2020. Among  
119 the 14 participants diagnosed with COVID-19 prior to the antibody tests, 10 (71.4%)  
120 tested positive for IgG antibodies.

121

## 122 **Discussion**

123 The prevalence of SARS-CoV-2 antibodies varies among countries and cities. Europe  
124 and northern America have high prevalence of SARS-CoV-2 antibodies, whereas  
125 Eastern Asia has a relatively low prevalence (3). In Japan, several studies conducted  
126 from June to September 2020 reported low seroprevalence of SARS-CoV-2 antibodies  
127 (0.03%–0.40%) in the general population (1). In this study, the seroprevalence of SAR-  
128 CoV-2 IgG antibodies among healthcare workers was 1.2% in August and October  
129 2020. It has been reported that the prevalence of SARS-CoV-2 antibodies in healthcare  
130 workers was higher than that in the general population (2,4). Our study also

131 demonstrated that the prevalence of SARS-CoV-2 antibodies was relatively higher in  
132 healthcare workers than in the general population in Japan.

133           The 20–29-year and 60–69-year age groups had high prevalence of SARS-CoV-  
134 2 IgG antibodies. Among the five participants in the 60–69-year age group who tested  
135 positive for IgG antibodies, four worked in the facility where nosocomial infection  
136 occurred in April 2020; therefore, the high prevalence among the 60–69-year age group  
137 was possibly due to nosocomial infection. The routes of infection in the 20–29-year age  
138 group have not been fully elucidated. However, the high occupational and daily activities  
139 and the demographic characteristics of asymptomatic carriers in the young age group  
140 were considered to be contributing factors.

141           The level of SARS-CoV-2 antibodies remain high for at least a few months after  
142 developing a COVID-19 infection (5–7). A recent study reported high levels of SARS-  
143 CoV-2 antibodies (69.0%–91.4%) 8 months after asymptomatic or mild SARS-CoV-2  
144 infection (8). In this study, 95% (21/22) of participants who had IgG antibodies in August  
145 tested positive for IgG antibodies in October. Among the participants who had a history  
146 of acquiring COVID-19, 71.4% (10/14) showed IgG positivity up to 6 months after  
147 infection. These results support those of previous studies, which reported that IgG  
148 antibodies can be detected in the majority of patients a few months after SARS-CoV-2



149 infection.

150           One limitation of this study is that only one antibody assay kit was used. As PCR  
151 tests or antigen tests were not conducted in participants with SARS-CoV-2 IgM or IgG  
152 antibodies, it remained uncertain whether false-positive data were included. In particular,  
153 among the eight participants who tested positive for IgM antibodies alone in August, none  
154 tested positive for IgG antibodies in October. We recruited individuals working at  
155 SOUSEIKAI medical group facilities for this study; of them, 91.6% (2,142 out of 2,338)  
156 in August and 90.0% (2,081 out of 2311) in October participated in this study. Thus, the  
157 effect of selection bias is limited.

158           In conclusion, the prevalence of SARS-CoV-2 IgG antibodies among healthcare  
159 workers in Japan was 1.2%, which was relatively higher than that in Japan's general  
160 population. Healthcare workers are at higher risk of infection; hence, they should be the  
161 top priority for further social support and SARS-CoV-2 vaccination.

162

163 **Acknowledgement**

164 The authors would like to thank SoftBank Group Corp. for providing the  
165 immunochromatographic assay kits, the workers at the study settings for their consent to  
166 participate and support in conducting this study, Ms. Junko Manabe and Yoshie Moriji  
167 for collecting the study data, and Editage ([www.editage.com](http://www.editage.com)) for providing English  
168 language editing assistance.

169

170 **Conflict of interest**

171 None to declare.

172

173 **Funding**

174 This study did not receive external funding. The immunochromatographic assay kits used  
175 in this study were provided by SoftBank Group Corp.

176

177 **Author contributions**

178 TYoshihara, RU, and SI conceived and designed the study. TY, KI, and SI wrote the  
179 protocol of the study. IA, RK, TT, TYonemura, KY, SN, YT, NY, and HK conducted the  
180 study in each study setting. TY, KI, MZ, and SI analyzed and interpreted the data. TY, KI,

181 MZ, and EC drafted the manuscript. All authors interpreted the results of the analyses,

182 critically reviewed and edited the manuscript, and approved the final version.

183

184

## References

185

- 186 1. Nawa N, Kuramochi J, Sonoda S, et al. Seroprevalence of SARS-CoV-2 IgG  
187 Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-  
188 CORONA): a household- and population-based study. medRxiv. 2020.  
189 doi: <https://doi.org/10.1101/2020.07.20.20155945>.
- 190 2. Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies  
191 and associated factors in healthcare workers: a systematic review and meta-  
192 analysis. *J Hosp Infect.* 2020;16(108):120-134. doi: 10.1016/j.jhin.2020.11.008.
- 193 3. Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence  
194 worldwide: a systematic review and meta-analysis. *Clin Microbiol Infect.*  
195 2020;S1198-743X(20)30651-0. doi: 10.1016/j.cmi.2020.10.020.
- 196 4. Abo-Leyah H, Gallant S, Cassidy D, et al. Seroprevalence of SARS-COV-2  
197 Antibodies in Scottish Healthcare Workers. medRxiv. 2020.  
198 doi: <https://doi.org/10.1101/2020.10.02.20205641>.
- 199 5. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to  
200 SARS-CoV-2 in Iceland. *N Engl J Med.* 2020;383(18):1724–34. doi:  
201 10.1056/NEJMoa2026116.

- 202 6. Flehmig B, Schindler M, Ruetalo N, et al. Persisting Neutralizing Activity to  
203 SARS-CoV-2 over Months in Sera of COVID-19 Patients. *Viruses*.  
204 2020;12(12):1357. doi: 10.3390/v12121357.
- 205 7. Wang Y, Li J, Li H, et al. Persistence of SARS-CoV-2-specific antibodies in  
206 COVID-19 patients. *Int Immunopharmacol*. 2021;90:107271. doi:  
207 10.1016/j.intimp.2020.107271.
- 208 8. Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after  
209 Asymptomatic or Mild SARS-CoV-2 Infection. *Emerg Infect Dis*.  
210 2021;27(3). doi: 10.3201/eid2703.204543.
- 211

212 Table 1. Prevalence of SARS2-CoV2 antibodies in August or October 2020 stratified by region

Region (prefecture)	August 2020				October 2020			
	n	Positive, n (%)			n	Positive, n (%)		
		IgM	IgG	IgM and/or IgG		IgM	IgG	IgM and/or IgG
Fukuoka	1,746	10 (0.6)	25 (1.4)	33 (1.9)	1,698	3 (0.2)	24 (1.4)	27 (1.6)
Kumamoto	321	0 (0)	0 (0)	0 (0)	308	0 (0)	0 (0)	0 (0)
Tokyo	75	0 (0)	0 (0)	0 (0)	75	0 (0)	0 (0)	0 (0)
Total	2,142	10 (0.5)	25 (1.2)	33 (1.5)	2,081	3 (0.1)	24 (1.2)	27 (1.3)
Comparison between the facilities where nosocomial infection occurred and in those where nosocomial infection did not occur								
Nosocomial infection (-)	1,654	10 (0.6)	13 (0.8)	21 (1.3)	1,595	3 (0.2)	13 (0.8)	16 (1.0)
Nosocomial infection (+)	488	0 (0)	12 (2.5)	12 (2.5)	486	0 (0)	11 (2.3)	11 (2.3)
P value <sup>a,b</sup>		0.09	0.003	0.06		0.34	0.009	0.03

213 <sup>a</sup>Pearson's chi-square test

214 <sup>b</sup>Comparison between the facilities where nosocomial infection occurred and those where nosocomial infection did not occur

215 Table 2. Prevalence of SARS-CoV-2 antibodies in August and/or October 2020  
216 stratified by COVID-19 history, decade age group, sex, and job categories

Characteristics	n	IgM Positive n (%)	IgG Positive n (%)	IgM and/or IgG Positive, n (%)
Total	2,160	10 (0.5)	28 (1.3)	36 (1.7)
COVID-19 history (-)	2,146	10 (0.5)	18 (0.8)	26 (1.2)
COVID-19 history (+)	14	0 (0)	10 (71.4)	10 (71.4)
<b>Age</b>				
20–29	411	2 (0.5)	11 (2.7)	12 (2.9)
30–39	587	3 (0.5)	1 (0.2)	3 (0.5)
40–49	601	3 (0.5)	7 (1.2)	10 (1.7)
50–59	330	0 (0.0)	4 (1.2)	4 (1.2)
60–69	174	2 (1.2)	5 (2.9)	7 (4.0)
≥70	57	0 (0.0)	0 (0.0)	0 (0.0)
P value <sup>d</sup>		0.60	0.006	0.007
<b>Sex</b>				
Female	1,547	6 (0.4)	21 (1.4)	27 (1.8)
Male	613	4 (0.7)	7 (1.1)	9 (1.5)
P value <sup>d</sup>		0.41	0.69	0.65
<b>Job categories</b>				
Nurse <sup>a</sup>	651	3 (0.5)	11 (1.7)	14 (2.2)
Physician	97	0 (0.0)	1 (1.0)	1 (1.0)
Technician <sup>b</sup>	369	2 (0.5)	3 (0.8)	4 (1.1)
Nursing care staff	329	2 (0.6)	8 (2.4)	9 (2.7)
Office worker	270	2 (0.7)	2 (0.7)	4 (1.5)
Receptionist	33	0 (0.0)	1 (3.0)	1 (3.0)
Clinical research unit worker	192	0 (0.0)	0 (0.0)	0 (0.0)
Other <sup>c</sup>	219	1 (0.5)	2 (0.9)	3 (1.4)
P value <sup>d</sup>		0.95	0.25	0.33

217 <sup>a</sup>Nurses include assistants

- 218 <sup>b</sup>Laboratory technicians, radiology technicians, pharmacists, clinical engineers, dental hygienists,  
219 physical therapists, occupational therapists, speech therapists, and acupuncturists  
220 <sup>c</sup>Drivers, security personnel, nursery school teachers, workers in shop, sanitary workers,  
221 nutritionists, and food service staff  
222 <sup>d</sup>Pearson's chi-square test